-
3 weeks ago | 
journals.plos.org | Kevin Rader |Shirley Wang |Aaron S. Kesselheim |Brandon J. Demkowicz
Loading metrics Open Access Peer-reviewedResearch Article Citation: Demkowicz BJ, Rader K, Wang SV, Kesselheim AS, Feldman WB (2025) The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study. PLoS Med 22(5): e1004596. https://doi.org/10.1371/journal.pmed.1004596Academic Editor: Alexander G.
-
2 months ago | 
ascpt.onlinelibrary.wiley.com | Shirley Wang |Massimiliano Russo |Robert J Glynn |Marie Bradley
WHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC? Real-world evidence involving healthcare database studies is well established for making causal inferences in post-market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. WHAT QUESTION DID THIS STUDY ADDRESS?
-
Feb 13, 2025 | 
onlinelibrary.wiley.com | Shirley Wang |Anton Pottegård
EDITORIAL Advancing Research Transparency and Reproducibility in Pharmacoepidemiology Shirley V. Wang, Corresponding Author Shirley V. Wang Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA Department of Msedicine, Harvard Medical School, Boston, Massachusetts, USA Correspondence: Shirley V.
-
Jan 9, 2025 | 
acrjournals.onlinelibrary.wiley.com | Elvira D'Andrea MD |Shirley Wang
No abstract is available for this article. Supporting Information Filename Description art43103-sup-0001-Disclosureform.pdfPDF document, 192.7 KB Disclosure Form
-
Oct 23, 2024 | 
nature.com | Shirley Wang |Jordyn R. Ricard |Yaniv Yacoby
AbstractSuicide risk is highest immediately after psychiatric hospitalization, but the field lacks methods for identifying which patients are at greatest risk, and when. We built personalized models predicting suicidal thoughts after psychiatric hospital visits (N = 89 patients), using ecological momentary assessment (EMA; average EMA responses per participant = 311).
-
Sep 17, 2024 | 
ascpt.onlinelibrary.wiley.com | Janick Weberpals |Shirley Wang
Regulators increasingly rely on real-world evidence generated from routine-care health data to evaluate novel therapies. Particularly, external control arms are increasingly used to supplement and contextualize efficacy and safety claims of single arm clinical trials for rare disease therapies. However, there are a number of methodological issues that may affect the validity of results derived from such comparisons.
-
Sep 4, 2024 | 
onlinelibrary.wiley.com | John Tazare |Shirley Wang |Rosa Gini |Daniel Prieto-Alhambra
This study aimed to quantify current trends of programming code sharing in pharmacoepidemiology research and provide recommendations on this topic. Out of 968 eligible “Pharmacoepidemiology and Drug Safety” articles between 2017 and 2022, 4.8% (N = 46) shared programming code. Code sharing increased from 1.8% in 2017 to 9.5% in 2022, with higher prevalence in methodological and simulation studies.
-
Sep 2, 2024 | 
onlinelibrary.wiley.com | Julien Kirchgesner |Hôpital Saint-Antoine |Shirley Wang |Sebastian Schneeweiss
Corresponding Author Julien Kirchgesner Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA AP-HP, Hôpital Saint-Antoine, Department of Gastroenterology, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France Correspondence: Julien Kirchgesner ([email protected]) Sebastian Schneeweiss ([email protected]) Search for...
-
Aug 17, 2024 | 
dx.doi.org | Alexandre Goyon |Shirley Wang |Kate Hofmann |Daniel Nguyen
-
Aug 13, 2024 | 
onlinelibrary.wiley.com | Priyanka Anand |Elvira D'Andrea |William B. Feldman |Shirley Wang
Conflicts of Interest Kueiyu Joshua Lin, Priyanka Anand, Jun Liu, Shirley V. Wang, Gregory Brill, and Elyse DiCesare have no conflicts of interest to disclose. Elvira D'Andrea is currently employed at and owns shares in AbbVie Inc. Outside of the current work, Dr. William Feldman serves as a consultant for Alosa Health and as an expert witness in litigation against inhaler manufacturers. He also served as a consultant for Aetion.
